Crinetics Pharmaceuticals, Inc.

CRNX

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001628280-26-014772
Filing date: Mar 4, 2026
Earliest execution date: Mar 3, 2026
Reporting Owners: Schilke Tobin (CFO)

Summary

Type

Sell

Net shares

-6,713

% of shares

-7.91%

Amount (USD)

$266,304

Insider confidence score

28.8 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Very large scheduled sell (<10% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-03

Code

S

Net shares

-6,713.0

Price per Share

$39.67

Amount (USD)

$266,304.71

Acquired/Disposed

Disposed

Shares Owned Before

84,834.0

Shares Owned After

78,121.0

Filing's footnotes

1. Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.